3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Unspecified Adult Solid Tumor, Protocol Specific
5
Prostatic Neoplasms
4
Multiple Myeloma
4
Lymphoma, Mantle-Cell
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Leukemia
4
Hodgkin Disease
4
Carcinoma, Non-Small-Cell Lung
4
Lymphoma, Non-Hodgkin
3
Lymphoma, Large-Cell, Immunoblastic
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, Follicular
3
Lymphoma, B-Cell, Marginal Zone
3
Lung Neoplasms
3
Leukemia, Myeloid, Chronic-Phase
3
Leukemia, Myeloid, Accelerated Phase
3
Kidney Neoplasms
3
Carcinoma, Renal Cell
3
Burkitt Lymphoma
3
Blast Crisis
3
Sezary Syndrome
2
Sarcoma
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Mycosis Fungoides
2
Melanoma
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, Large-Cell, Anaplastic
2
Interventions
Cyclophosphamide
32
Tacrolimus
29
fludarabine
27
Mycophenolic Acid
23
fludarabine phosphate
22
Busulfan
19
Whole-Body Irradiation
18
Melphalan
16
Methotrexate
15
Antilymphocyte Serum
14
Rituximab
12
Bortezomib
11
Stem Cell Transplantation
10
Cyclosporine
10
thymoglobulin
9
Sirolimus
9
Granulocyte Colony-Stimulating Factor
9
Peripheral Blood Stem Cell Transplantation
8
Thiotepa
7
Interviews as Topic
7
Filgrastim
7
Dexamethasone
7
Clofarabine
7
Blood Specimen Collection
6
Alemtuzumab
6
merphos
5
Voriconazole
5
Standard of Care
5
Nivolumab
5
Lenalidomide
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Hematologic Neoplasms
×
tanespimycin
×
Clear all
NCT00113204
2008-05-20
IPi-504-01
Infinity Pharmaceuticals, Inc.
Phase 1
Completed
18 enrolled